Magnetic resonance imaging, proton magnetic resonance spectroscopy and cerebrospinal fluid abnormalities in multiple sclerosis

  • I. L. Simone
  • C. Tortorella
  • P. Giannini
  • M. Trojano
  • P. Livrea
Conference paper


Magnetic resonance imaging (MRI) is acknowledged as the most sensitive tool for the diagnosis of multiple sclerosis (MS). This technique is not only the procedure of choice in demonstrating plaque dissemination, but it could also allow a prospective evaluation of evolution of the disease processes. Acute and chronic demyelinating plaques appear as areas of increased signal intensity on proton density and T2-weighted images [1]. In addition, the use of gadopentate dimeglumine (Gd-DTPA), a paramagnetic contrast agent sensitive to changes in blood-brain barrier (BBB) permeability, allows the identification of new or acute lesions in T1-weighted images. Serial Gd-MRI studies have provided further information regarding the pathogenesis and behaviour of MS demyelinating areas, suggesting that the disease activity may be active even in clinically stable phase [2, 3]. Gd-DTPA enhancement has been advocated as a means of monitoring disease activity since enhanced areas represent an early, and perhaps even the initial, event in new MS lesion development [2, 4]. Correlations between MRI and histopathological findings in experimental chronic encephalomyelitis showed that Gd-enhancement was associated with increased endothelial vesicular transport as a mechanism of BBB breakdown [5]. Furthermore, the level of contrast enhancement was related to the degree of macrophage infiltration more than to perivascular lymphocyte reaction, suggesting that lymphocytes may play a lesser role in BBB breakdown [6].


Multiple Sclerosis Myelin Basic Protein Multiple Sclerosis Lesion Magnetic Resonance Imaging Lesion Magnetic Resonance Imaging Activity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Paty DW, Oger JJF, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, Eisen KA, Purves SJ, Low MD, Brandejs V, Robertson WD, Li DKB (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligo-clonal banding, and CT. Neurology 38:180–185PubMedGoogle Scholar
  2. 2.
    Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, Kingsley DPE, Moseley IF, du Boulay EPGH, McDonald WI (1990) Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 40: 229–235PubMedGoogle Scholar
  3. 3.
    Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29: 548–555PubMedCrossRefGoogle Scholar
  4. 4.
    Grossmann RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzales-Scarano F (1988) Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 169:117–122Google Scholar
  5. 5.
    Hawkins CP, Mackenzie F, Tofts P, du Boulay EPGH, McDonald WI (1991) Patterns of blood-brain breakdown in inflammatory demyelination. Brain 114: 801–810PubMedCrossRefGoogle Scholar
  6. 6.
    Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M (1991) Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 180: 467–474PubMedGoogle Scholar
  7. 7.
    McDonald WI, Miller DH, Barnes D (1992) The pathological evaluation of multiple sclerosis [review]. Neuropathol Appl Neurobiol 18: 319–334PubMedCrossRefGoogle Scholar
  8. 8.
    Prineas JW, Kwon EE, Cho E-S, Sharer LR (1984) Continual break-down and regeneration of myelin progressive multiple sclerosis plaques. Ann NY Acad Sci 436:11–32PubMedCrossRefGoogle Scholar
  9. 9.
    Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho E-S (1993) Multiple sclerosis: re-myelination of nascent lesions. Ann Neurol 33:137–151PubMedCrossRefGoogle Scholar
  10. 10.
    Roizin L, Haymaker W, D’Amelio F (1982) Disease states involving the white matter of the central nervous system. In: Haymaker W, Adams RD (eds) Histology and histopathology of the nervous system. Springfield, III, Thomas, pp 1276–1324Google Scholar
  11. 11.
    Duchen LW (1984) General pathology of neurons and neuroglia. In: Adams JH, Corsel-lis JAN, Duchen LW (eds) Greenfield’s Neuropathology. London, Edward Arnold, pp 1–52Google Scholar
  12. 12.
    Filippi M, Paty DW, Kappos L, Barkhof F, Compston DAS, Thompson AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH (1995) Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis. A follow-up study. Neurology 45: 255–260PubMedGoogle Scholar
  13. 13.
    Richard TL (1991) Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. AJR: 1073–1078Google Scholar
  14. 14.
    Kugel H, Heindel W, Ernestus R, Bune J, du Mesnil R, Friedman G (1992) Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 183: 701–709PubMedGoogle Scholar
  15. 15.
    Henriksen O, Gideon P, Sperling B, Skyhoj T, Jogensen HS, Arlien-Soborg P (1992) Cerebral lactate production and blood flow in acute stroke. J Magn Reson Imaging 2: 511–517PubMedCrossRefGoogle Scholar
  16. 16.
    Arnold DL, Matthews PM, Francis G, Antel J (1990) Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 14:154–159PubMedCrossRefGoogle Scholar
  17. 17.
    Matthews PM, Francis GS, Antel J, Arnold DL (1991) Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 41: 1251–1256PubMedGoogle Scholar
  18. 18.
    Frahm J, Michaelis T, Merboldt KD, Bruhn H, Gyngell ML, Hänicke W (1990) Improvements in localized proton NMR spectroscopy of human brain. Water suppression, short echo times and 1 ml resolution. J Magn Reson 290: 464–473Google Scholar
  19. 19.
    Arnold DL, Matthews PM, Francis GS, O’Connor J, Antel JP (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 31: 235–241PubMedCrossRefGoogle Scholar
  20. 20.
    De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL (1995) Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 38: 901–909PubMedCrossRefGoogle Scholar
  21. 21.
    Lopez-Villegas D, Lenkinski RE, Wehrli SL, Ho WZ, Douglas SD (1995) Lactate production by human monocytes/macrophages determined by proton MR spectroscopy. Magn Reson Med 34: 32–38PubMedCrossRefGoogle Scholar
  22. 22.
    Simone IL, Tortorella C, Liguori M, Giannini P, Picciola E, Carrara D, Federico F, Livrea P (1995) Biochemical changes in cerebrospinal fluid (CSF) and demyelinating area in multiple sclerosis (MS). Evaluation by proton magnetic resonance spectroscopy OH-MRS). J Neuroimmunol 1: 73CrossRefGoogle Scholar
  23. 23.
    Miller BL (1991) Review of chemical issue in 1H-NMR spectroscopy: N-acetyl-L- aspartate, creatine and choline. NMR Biomed 4: 47–52PubMedCrossRefGoogle Scholar
  24. 24.
    Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI (1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis. Brain 117:49–58PubMedCrossRefGoogle Scholar
  25. 25.
    Adams CWM, Poston RN, Buk SJ (1989) Pathology, histochemistry and immunocyto-chemistry of lesions in acute multiple sclerosis. J Neurol Sci 92: 291–306PubMedCrossRefGoogle Scholar
  26. 26.
    Bruhn H, Frahm J, Merboldt KD, Hänicke W, Hanefeld F, Christen HJ, Kruse B, Bauer HJ (1992) Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 32:140–150PubMedCrossRefGoogle Scholar
  27. 27.
    Koopmans RA, Li DKB, Zhu G, Allen PS, Penn A, Paty DW (1993) Magnetic resonance spectroscopy of multiple sclerosis: in vivo-detection of myelin breakdown product [letter]. Lancet 341: 631–632PubMedCrossRefGoogle Scholar
  28. 28.
    García-Buñuel L, García-Bunel VM (1965) Cerebrospinal fluid levels of free myoinositol in some neurological disorders. Neurology 15: 348–350PubMedGoogle Scholar
  29. 29.
    Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45: 37–45PubMedCrossRefGoogle Scholar
  30. 30.
    Patel TB, Clark JB (1979) Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 184: 539–546PubMedGoogle Scholar
  31. 31.
    Koschorek F, Offermann W, Stelten J, Braunsdorf WE, Steiler U, Gremmel H, Leibfritz D (1993) High-resolution 1H-NMR spectroscopy of cerebrospinal fluid in spinal diseases. Neurosurg Rev 16: 307–315PubMedCrossRefGoogle Scholar
  32. 32.
    Lynch J, Peeling J, Auty A, Sutherland GR (1993) Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis. Can J Neurol Sci 20:194–198PubMedGoogle Scholar
  33. 33.
    Livrea P, Trojano M, Simone IL, Zimatore GB, La Montanara G, Leante R (1981) Intrathecal IgG synthesis in multiple sclerosis: comparison between isoelectric focusing and quantitative estimation of cerebrospinal fluid IgG. J Neurol 224:159–169PubMedCrossRefGoogle Scholar
  34. 34.
    Norrby E (1978) Viral antibodies and multiple sclerosis. Progr Med Virol 241:1–39Google Scholar
  35. 35.
    Warren KG, Catz J (1989) Cerebrospinal fluid autoantibodies to myelin basic protein in multiple sclerosis patients. J Neurol Sci 91:143–151PubMedCrossRefGoogle Scholar
  36. 36.
    Sun JB (1993) Autoreactive T and B cells in nervous system diseases. Acta Neurol Scand S142:1–56Google Scholar
  37. 37.
    Xiao G-B, Linington C, Link H (1991) Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroim-munol 31: 91–96CrossRefGoogle Scholar
  38. 38.
    Baig S, Olsson T, Jiang Y-P, Höjerberg B, Cruz M, Link H (1991) Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid. Scand J Immunol 33: 73–79PubMedCrossRefGoogle Scholar
  39. 39.
    Warren KG, Catz I (1985) The relationship between levels of cerebrospinal fluid myelin basic protein and IgG measurements in patients with multiple sclerosis. Ann Neurol 17: 475–480PubMedCrossRefGoogle Scholar
  40. 40.
    Baumhefner RW, Tourtellotte WW, Syndulko K, Waluch V, Ellison GW, Meyers LW, Cohen SN, Osborne M, Shapshak P (1990) Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging. Arch Neurol 47: 19–26PubMedCrossRefGoogle Scholar
  41. 41.
    Kappos L, Pfeuffer B, Staedt D, Rohrbach E, Heun R, Haubitz I, Keil W (1988) Quantitative magnetic resonance imaging of the multiple sclerosis brain: localization rather than total volume of lesions correlates with cerebrospinal fluid IgG level and visual evoked response abnormalities. Ann Neurol 24: 169Google Scholar
  42. 42.
    Baum K, Nehrig C, Girke W, Bräu H, Schörner W (1990) Multiple sclerosis: relations between MRI and CT findings, cerebrospinal fluid parameters and clinical features. Clin Neurol Neurosurg 92: 49–56PubMedCrossRefGoogle Scholar
  43. 43.
    Barkhof F, Frequin STFM, Hommes OR, Lamers K, Seheltens P, van Geel WJA, Valk J (1992) A correlative triad of gadolinium-DTPA, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous metylprednisolone. Neurology 42:63–67PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1996

Authors and Affiliations

  • I. L. Simone
    • 1
  • C. Tortorella
    • 1
  • P. Giannini
    • 1
  • M. Trojano
    • 1
  • P. Livrea
    • 1
  1. 1.Institute of Clinical NeurologyUniversity of BariBariItaly

Personalised recommendations